Cost burden of disease progression high in multiple myeloma
(HealthDay)—The economic burden of disease progression is considerable among multiple myeloma (MM) patients receiving drug therapy across all lines of therapy (LOTs), according to a study published online Aug. 7 in Leukemia ...
Aug 15, 2019
0
4